Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Plus: One Step Forward For Veklury, Two Steps Back For REGEN-COV
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.
You may also be interested in...
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.
Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.